US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

This court ruling serves as a strategic tailwind for J&J (JNJ), effectively removing a legal overhang that threatened its prostate cancer franchise, though the impact remains muted by current technical exhaustion. JNJ’s RSI at 32.51 indicates oversold conditions nearing a bounce zone, yet the MACD crossover confirms a persistent bearish momentum that warrants caution despite this positive litigation outcome. Fundamental data from recent 10-Q filings highlights that JNJ’s robust free cash flow and diversified portfolio provide a floor, making the $230 support level critical for defensive positioning. Conversely, the ruling accelerates competitive pressure on Bayer (BAYRY), likely weighing on their pharmaceutical margins and exacerbating their already precarious technical downtrend. Traders should look for a confirmed daily close above $238 to signal a momentum reversal for JNJ, while those maintaining exposure should monitor the $230 support—a break below this level would trigger a technical volume vacuum and potentially accelerate a move toward the $224 psychological support. Confluence between this legal win and JNJ's oversold status suggests a tactical entry opportunity for long-term holders, provided the broader market environment doesn't force a breach of major support levels.